We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.60 | 0.22% | 269.98 | 269.00 | 270.00 | 271.68 | 265.72 | 265.72 | 2,436,960 | 00:56:05 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Amgen Inc. (AMGN) Thursday said Repatha will only be available at its lower list price next year as the company works to make the cholesterol drug more affordable.
Amgen last year cut the list price of Repatha by 60% to $5,850 a year in a bid to reduce out-of-pocket costs, especially for Medicare patients.
The Thousand Oaks, Calif., biotechnology company also continued to offer the original list price option of more than $14,000 to minimize disruption in the supply chain and allow time for payers and pharmacy benefit managers to modify existing contracts.
Amgen, which reported $91 million in U.S. Repatha sales for the second quarter, said it will discontinue the Repatha original list price option Dec. 31.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 24, 2019 09:38 ET (13:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
